Policy/Enforcement News
Prescription Drug Affordability Board Activity through January 27, 2025
Prescription Drug Affordability Board Activity through January 27, 2025 Activities Summary Colorado: On January 17th, the PDAB reviewed Draft Upper Payment Limit Data Submission Guidance to discuss whether it was sufficient to begin an upper payment limit review on Enbrel at the March 7th meeting. A January 23rd meeting of Colorado’s PDAAC involved reviewing the…
[...]Prescription Drug Affordability Board Activity through December 18, 2024
Prescription Drug Affordability Board Activity through December 18, 2024 Activities Summary Colorado: The Prescription Drug Affordability Board (PDAB) met on December 6, 2024 to hear and discuss public comment before proposing and approving revisions to policy and procedures around affordability reviews. The PDAB updated the state’s Prescription Drug Affordability Review Board and Advisory Council (PDAAC)…
[...]Prescription Drug Affordability Board Activity through November 15, 2024
Colorado’s board reviewed proposed changes to PDAB legislation based on stakeholder testimony and board review and learned about Medicare’s Maximum Fair Price (MFP) determination. Over two meetings, Oregon’s board reviewed a draft constituent group engagement report and a UPL model that analyzed potential 2023 savings based upon MFP provided by their consultants and aggregate data collected from PBMs. The board also discussed ; policy recommendations from staff and a UPL draft report required by Senate Bill 192.
[...]Prescription Drug Affordability Board Activity through October 18, 2024
Colorado’s board reviewed proposed changes to PDAB legislation based on stakeholder testimony and board review and learned about Medicare’s Maximum Fair Price (MFP) determination. Over two meetings, Oregon’s board reviewed a draft constituent group engagement report and a UPL model that analyzed potential 2023 savings based upon MFP provided by their consultants and aggregate data collected from PBMs. The board also discussed ; policy recommendations from staff and a UPL draft report required by Senate Bill 192.
[...]A DSCSA-newbies guide to the recent FDA DSCSA announcement
The FDA recently announced that “connected trading partners” that have made progress in transmitting electronic data that identifies and follow medicines made for the U.S. drug supply will not be penalized if they are still working out challenges in the process. Are you wondering what that means? We can explain.
[...]PSM Advocates for SHOP SAFE legislation at Anti-Counterfeiting Day on the Hill
Our Executive Director, Shabbir Safdar, along with PSM members, shared examples of pharmaceutical counterfeits and helped attendees understand why current systems for stopping counterfeit product sales do not work well.
[...]Prescription Drug Affordability Board Activity through August 15, 2024
Colorado clarifies who their Upper Payment Limit rule applies to. Maryland picks six drugs to conduct cost reviews for and requests information from the public in an effort to produce something by year end. Oregon pauses affordability reviews for 2024 while it gathers feedback from stakeholders. Washington considers the eligibility criteria for drugs to be reviewed, looking to states like Colorado for guidance.
[...]Prescription Drug Affordability Boards
Prescription Drug Affordability Boards States across the country are experimenting with Prescription Drug Affordability Boards (PDABs) to address the price of medicine. Each state has a different approach. Several exist to negotiate supplemental Medicaid rebates; others make recommendations to limit costs. A third group of PDABs is particularly concerning because they have the power to…
[...]PSM testimony: Colorado Prescription Drug Affordability Board Meeting, June 7, 2024
A Colorado board is considering setting a price limit on the medicine Stelara. This will have unintended consequences, undermining the safety of the supply chain for this medicine and limiting patient access. Learn more by reading our testimony.
[...]How Upper Payment Limits on medicine increase the risk of diverted and counterfeit medicine in the drug supply
States like Colorado are experimenting with Prescription Drug Affordability Boards to address the price of medicine, but solutions like Upper Payment Limits will yield multiple unintended consequences that will do more harm than good to patients.
[...]